financetom
Business
financetom
/
Business
/
JPMorgan profit drops as loan loss provisions eclipse investment banking
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
JPMorgan profit drops as loan loss provisions eclipse investment banking
Oct 11, 2024 4:15 AM

(Reuters) -JPMorgan Chase's ( JPM ) profit dropped in the third quarter as a bigger provision for potential loan defaults offset gains from investment banking, the bank said on Friday.

Banks are building up stockpiles - which act as a safeguard when borrowers default on their loans - to typical levels as consumers deplete the savings they built up during the pandemic.

Consumers' financial health remains solid despite elevated interest rates and fears over unemployment.

Still, CEO Jamie Dimon maintained his guarded tone on the economy, despite stock markets reaching record highs and the Federal Reserve beginning a long-awaited cycle of rate cuts.

"We have been closely monitoring the geopolitical situation for some time, and recent events show that conditions are treacherous and getting worse," Dimon said.

"There is significant human suffering and the outcome of these situations could have far-reaching effects on both short-term economic outcomes and more importantly on the course of history."

Net interest income (NII) - the difference between what a lender earns on loans and pays on deposits - grew 3% to $23.5 billion.

The bank's Wall Street operations were a bright spot as the prospect of monetary easing by the Fed spurred a rally in equities in the third quarter.

Investment banking revenue grew 29% to $2.4 billion. This is higher than the management's guidance of 15% last month.

The lender set aside $3.11 billion as provisions for credit losses, compared with $1.38 billion a year earlier.

Profit was $12.90 billion for the three months ended Sept. 30, compared with $13.15 billion a year ago.

Shares rose about 1% to $214.79 in premarket trading.

(Reporting by Niket Nishant in Bengaluru and Nupur Anand in New York, Editing by Lananh Nguyen and Arun Koyyur)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Applovin Insider Sold Shares Worth $19,791,420, According to a Recent SEC Filing
Applovin Insider Sold Shares Worth $19,791,420, According to a Recent SEC Filing
Aug 21, 2024
07:43 AM EDT, 08/21/2024 (MT Newswires) -- Eduardo Vivas, Director, on August 16, 2024, sold 229,200 shares in Applovin ( APP ) for $19,791,420. Following the Form 4 filing with the SEC, Vivas has control over a total of 7,654,698 shares of the company, with 7,412,475 shares held directly and 242,223 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1751008/000156218024006421/xslF345X03/primarydocument.xml Price: 86.75, Change: +0.17,...
Enterprise Products to Acquire Pinon Midstream for $950 Million
Enterprise Products to Acquire Pinon Midstream for $950 Million
Aug 21, 2024
07:37 AM EDT, 08/21/2024 (MT Newswires) -- An Enterprise Products Partners ( EPD ) affiliate has agreed to acquire Pinon Midstream for $950 million in a debt-free cash transaction, the companies said Wednesday. The deal includes around 50 miles of natural gas pipelines, five 3-stage compressor stations, treating facilities, and acid gas injection wells, according to the joint statement. The...
Lexicon Pharmaceuticals Says FDA to Hold Meeting in October to Review Zynquista for Type 1 Diabetes, CKD
Lexicon Pharmaceuticals Says FDA to Hold Meeting in October to Review Zynquista for Type 1 Diabetes, CKD
Aug 21, 2024
08:30 AM EDT, 08/21/2024 (MT Newswires) -- Lexicon Pharmaceuticals ( LXRX ) said Wednesday that the US Food and Drug Administration is expected to hold an Endocrinologic and Metabolic Drugs Advisory Committee meeting on Oct. 31 to review Zynquista for use with insulin in type 1 diabetes and chronic kidney disease. The Prescription Drug User Fee Act, or PDUFA, goal...
Ford changes EV plans, will delay pickup truck, axe three-row SUV
Ford changes EV plans, will delay pickup truck, axe three-row SUV
Aug 21, 2024
DETROIT (Reuters) -Ford Motor ( F ) is reshuffling its electric vehicle plans, killing its three-row SUV and delaying its next-generation pickup while adding a new pickup and van to its future lineup as it adjusts to slower-than-expected EV growth. The automaker will take a special non-cash charge of about $400 million for the write-down of certain assets for the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved